Date: 2015-06-17
Type of information: Licensing agreement
Compound: antibody library n-CoDeR®
Company: BioInvent (Sweden) undisclosed leading U.S. biotechnology company (USA)
Therapeutic area: undisclosed
Type agreement: licensing
Action mechanism: monoclonal antibody. The n-CoDeR® antibody library contains 30 billion functional human antibody genes (genes with open reading frame). All the antibodies have the same framework structure, which has low immunogenicity. However, the antibodies have different combinations of Complementarity Determining Regions (CDRs), which define the antigen binding specificity. These CDRs were originally isolated from the antibody genes of a large number of healthy volunteers. Using the n-CoDeR® technology the fully human CDRs are recombined into new antibody molecules. The unique recombination process allows the library to contain a wider variety of antibodies than could have been created naturally by the human immune system. This means that there is a higher likelihood of finding antibodies with high affinity and high specificity against a particular target.
Disease: undisclosed
Details: * On June 17, 2015, BioInvent International announced that its partnership with a leading U.S. biotechnology company advances to next phase. The collaboration aims to discover novel therapeutic antibodies to be incorporated into the U.S. company’s CAR-T programs. The unnamed biotech company signed earlier this year a license to get access to BioInvent\'s unique ability to discover antibodies with the antibody library n-CoDeR®. The first of up to three targets covered by the agreement has now been identified and the work to develop appropriate antibodies can thus be initiated. CAR-Ts are T cells that have been removed from the body and attached through genetic engineering to an antibody fragment that recognizes a specific tumor protein. The result is a cancer immunotherapy drug with the killing power of a greatly enhanced T cell, combined with the tumor-targeting ability of an antibody.
Financial terms: Under the license agreement BioInvent may receive revenue in the form of potential clinical milestone payments and royalties on future sales of any product developed as a result of the collaboration. In addition, BioInvent is in the early phase of the collaboration entitled to limited compensation for the work to identify antibodies against the first target.
Latest news:
